With antiretroviral therapy for adults with HIV infection continuing to evolve, the International AIDS Society USA Panel has issued updated recommendations for the treatment of HIV, according to a report in the August 16 issue of JAMA, a theme issue on HIV/AIDS.

Scott M. Hammer, M.D., of the Columbia University College of Physicians and Surgeons, New York, presented the recommendations of the report today at a JAMA media briefing at the International AIDS Conference in Toronto.

In the last 25 years, acquired immunodeficiency syndrome (AIDS) has grown to pandemic proportions, resulting in 25 million deaths worldwide and an estimated 40 million persons living with human immunodeficiency virus (HIV), according to background information in the article. Guidelines for antiretroviral therapy are important for clinicians worldwide given the complexity of the field and the varied clinical situations in which these agents are used.

To provide physicians and other HIV clinicians with current recommendations for the use of antiretroviral therapy in HIV-infected adults in circumstances for which there is relatively unrestricted access to drugs and monitoring tools, the International AIDS SocietyUSA (IAS-USA) panel has updated its recommendations as warranted by new developments in the field. The 16-member noncompensated panel was appointed, based on expertise in HIV research and patient care internationally. Data published or presented at selected scientific conferences since mid-2004 through May 2006 were identified and reviewed by all members of the panel. The researchers identified 181 citations regarding antiretroviral agent trials that were considered potentially relevant.

New guidelines were drafted by a writing committee and reviewed by the entire panel. The recommendations of the panel are centered on 4 key issues: when to start antiretroviral therapy; what to start; when to change; and what to change.

The resea
'"/>

Contact: Elizabeth Streich
212-305-6535
JAMA and Archives Journals
13-Aug-2006